Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 3/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805953 | 1.00 | FGFR4 (0.45) | FGFR4GPR52GPR142RAF1SCN9A | |
| SCHEMBL12959030 | 1.00 | FGFR4 (0.45) | FGFR4GPR52GPR142RAF1SCN9A | |
| SCHEMBL12653828 | 0.92 | FGFR4 (0.45) | FGFR4GPR52GPR142RAF1SCN9A | |
| SCHEMBL18415689 | 0.90 | FGFR4 (0.43) | FGFR4GPR142RAF1SCN9APRMT5 | |
| SCHEMBL18415688 | 0.90 | FGFR4 (0.43) | FGFR4GPR142RAF1SCN9APRMT5 | |
| SCHEMBL17655352 | 0.90 | FGFR4 (0.43) | FGFR4GPR142RAF1SCN9APRMT5 | |
| SCHEMBL12653773 | 0.90 | FGFR4 (0.38) | FGFR4GPR52RAF1PRMT5WDR77 | |
| SCHEMBL17655444 | 0.89 | FGFR4 (0.42) | FGFR4GPR52GPR142RAF1PRMT5 | |
| SCHEMBL17655412 | 0.88 | FGFR4 (0.46) | FGFR4GPR52GPR142RAF1CA2 | |
| SCHEMBL17655353 | 0.88 | RAF1 (0.39) | FGFR4GPR52RAF1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1940/4885GPR52 3134/4885GPR142 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.